



Antibody against Viral Infection: Advances in the Era of Therapeutic Monoclonal Antibody

Guest Editor:

Dr. Laurent Dacheux

Institut Pasteur, National Reference Centre for Rabies, WHO Collaborating Center for Reference and Research on Rabies, Lyssavirus Epidemiology and Neuropathology Unit, 75724 Paris, France

Deadline for manuscript submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

Antibodies are one of the key components of the immune system to control viral infections. The control by this armed component of the humoral immunity is dual, based on direct interference with the viral replication process (mainly through a neutralization effect on virions) or by targeting infected cells to immune effector cells. The recent advent of the era of monoclonal antibodies, made possible by hybridoma technology, has opened new avenues in the field of therapeutics for viral disease.

This Special Issue of Vaccines is open to original reports, perspectives, reviews, or research articles focusing on recent advances on the use of antibodies against viral infection. The submission of articles covering the following research areas is especially encouraged:

- Experimental development, characterization, or clinical evaluation of novel or existing antiviral antibodies;
- Mechanisms of antiviral activities of antibodies;
- Development of vaccine strategies to elicit antiviral antibodies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)